\-\ Texto\\:\\ \ \(0\)\
\-\ mildly\\ decreased\\ sensation\\ to\\ touch\\ in\\ the\\ upper\\ extremities\\ with\\ no\\ motor\\ weakness\\.\\ normal\\ balance\\,\\ and\\ vision\\ with\\ no\\ current\\ visual\\ deficits\\.\ \(0\)\
\-\ the\\ patient\\ is\\ currently\\ on\\ pharmacological\\ therapy\\ for\\ multiple\\ sclerosis\\.\\ she\\ has\\ had\\ a\\ chronic\\,\\ intermittant\\ course\\,\\ so\\ far\\,\\ and\\ seems\\ to\\ be\\ slightly\\ progressing\\ in\\ symptomatology\\.\\ she\\ currently\\ has\\ no\\ symptoms\\ of\\ optic\\ neuritis\\.\ \(0\)\
\-\ axial\\ flair\\ mri\\ sequences\\ demonstrate\\ multiple\\ small\\ foci\\ of\\ increased\\ signal\\ intensity\\ in\\ the\\ periventricular\\ white\\ matter\\ which\\ had\\ increased\\ in\\ number\\ compared\\ to\\ prior\\ mri\\ performed\\ four\\ years\\ prior\\.\\ the\\ left\\ optic\\ nerve\\ was\\ enlarged\\ on\\ the\\ axial\\ t2wi\\ from\\ 2001\\ consistent\\ with\\ the\\ patients\\ symptoms\\ of\\ left\\ optic\\ neuritis\\.\\ the\\ left\\ optic\\ nerve\\ has\\ normalized\\ on\\ the\\ current\\ examination\\ with\\ treatment\\ and\\ the\\ symptoms\\ of\\ optic\\ neuritis\\ have\\ resolved\\.\ \(0\)\
\-\ multiple\\ sclerosis\ \(41\)\
\-\ multiple\\ sclerosis\\,\\ lyme\\ disease\\,\\ migraine\\ headaches\\,\\ vasculitis\\.\ \(0\)\
\-\ 41\\ year\\ old\\ female\\ who\\ originally\\ presented\\ with\\ left\\ optic\\ neuritis\\ in\\ 2001\\,\\ and\\ who\\ was\\ subsequently\\ diagnosed\\ with\\ multiple\\ sclerosis\\ presented\\ to\\ neurology\\ clinic\\ with\\ new\\ bilateral\\ arm\\ numbness\\.\ \(0\)\
\-\ this\\ case\\ deomonstrated\\ an\\ abnormally\\ enlarged\\ left\\ optic\\ nerve\\ in\\ 2001\\,\\ at\\ which\\ time\\ her\\ first\\ mri\\ was\\ performed\\.\\ he\\ optic\\ neuritis\\ has\\ currently\\ resolved\\,\\ but\\ she\\ is\\ presenting\\ with\\ worsening\\ upper\\ extremity\\ numbness\\.\\ her\\ current\\ mri\\ shows\\ progression\\ in\\ the\\ number\\ of\\ abnormal\\ foci\\ in\\ the\\ periventricular\\ white\\ matter\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ optic\\:\\ 0\\.13185686732016086\ \(0\)\
\-\ neuritis\\:\\ 0\\.11279835504800713\ \(0\)\
\-\ 2001\\:\\ 0\\.05673565381188054\ \(0\)\
\-\ sclerosis\\:\\ 0\\.05115525389043908\ \(0\)\
\-\ current\\:\\ 0\\.050041675857426006\ \(0\)\
\-\ currently\\:\\ 0\\.04232715993765072\ \(0\)\
\-\ periventricular\\:\\ 0\\.041030817715465594\ \(0\)\
\-\ nerve\\:\\ 0\\.03848682658109133\ \(0\)\
\-\ multiple\\:\\ 0\\.0374959584058181\ \(0\)\
\-\ deomonstrated\\:\\ 0\\.03673132676652707\ \(0\)\
\-\ number\\:\\ 0\\.03551367943638298\ \(0\)\
\-\ resolved\\:\\ 0\\.034522413245871596\ \(0\)\
\-\ numbness\\:\\ 0\\.03421656852211804\ \(0\)\
\-\ mri\\:\\ 0\\.032721264248577\ \(0\)\
\-\ foci\\:\\ 0\\.030566866226275375\ \(0\)\
\-\ pharmacological\\:\\ 0\\.030025335464718323\ \(0\)\
\-\ intermittant\\:\\ 0\\.030025335464718323\ \(0\)\
\-\ normalized\\:\\ 0\\.030025335464718323\ \(0\)\
\-\ she\\:\\ 0\\.029984826768177153\ \(0\)\
\-\ matter\\:\\ 0\\.028037333086673315\ \(0\)\
\-\ has\\:\\ 0\\.026744999508237964\ \(0\)\
\-\ symptoms\\:\\ 0\\.02662071846122674\ \(0\)\
\-\ enlarged\\:\\ 0\\.024296842253200054\ \(0\)\
\-\ seems\\:\\ 0\\.023666767533488953\ \(0\)\
\-\ white\\:\\ 0\\.02361753510593348\ \(0\)\
\-\ progressing\\:\\ 0\\.023489435806743966\ \(0\)\
\-\ symptomatology\\:\\ 0\\.022998673158175706\ \(0\)\
\-\ migraine\\:\\ 0\\.022998673158175706\ \(0\)\
\-\ lyme\\:\\ 0\\.022038157913959737\ \(0\)\
\-\ balance\\:\\ 0\\.021799997856293284\ \(0\)\
\-\ neurology\\:\\ 0\\.021685835463842805\ \(0\)\
\-\ her\\:\\ 0\\.021411763820707797\ \(0\)\
\-\ t2wi\\:\\ 0\\.021360995707719006\ \(0\)\
\-\ axial\\:\\ 0\\.020323262300565595\ \(0\)\
\-\ far\\:\\ 0\\.0201105599058426\ \(0\)\
\-\ originally\\:\\ 0\\.0201105599058426\ \(0\)\
\-\ left\\:\\ 0\\.019918859776519054\ \(0\)\
\-\ performed\\:\\ 0\\.019854819426894325\ \(0\)\
\-\ abnormally\\:\\ 0\\.019602685665804944\ \(0\)\
\-\ presented\\:\\ 0\\.019411313625186742\ \(0\)\
\-\ touch\\:\\ 0\\.019211774185731386\ \(0\)\
\-\ 41\\:\\ 0\\.01897016061218826\ \(0\)\
\-\ who\\:\\ 0\\.01856640340951418\ \(0\)\
\-\ prior\\:\\ 0\\.01828427310168636\ \(0\)\
\-\ vasculitis\\:\\ 0\\.01822027986448409\ \(0\)\
\-\ progression\\:\\ 0\\.01771320930207776\ \(0\)\
\-\ increased\\:\\ 0\\.01742070651499713\ \(0\)\
\-\ upper\\:\\ 0\\.017184004211405986\ \(0\)\
\-\ vision\\:\\ 0\\.01644993322296215\ \(0\)\
\-\ sensation\\:\\ 0\\.016354872065603102\ \(0\)\
\-\ flair\\:\\ 0\\.01632366093339828\ \(0\)\
\-\ deficits\\:\\ 0\\.016292681856366953\ \(0\)\
\-\ so\\:\\ 0\\.016201103078372057\ \(0\)\
\-\ visual\\:\\ 0\\.016141150005654976\ \(0\)\
\-\ subsequently\\:\\ 0\\.016141150005654976\ \(0\)\
\-\ clinic\\:\\ 0\\.015909608959176598\ \(0\)\
\-\ four\\:\\ 0\\.01545655395860799\ \(0\)\
\-\ had\\:\\ 0\\.015365415160339235\ \(0\)\
\-\ mildly\\:\\ 0\\.01516403621413612\ \(0\)\
\-\ compared\\:\\ 0\\.015070922469586136\ \(0\)\
\-\ arm\\:\\ 0\\.014912818588068954\ \(0\)\
\-\ motor\\:\\ 0\\.014868726465858384\ \(0\)\
\-\ sequences\\:\\ 0\\.014868726465858384\ \(0\)\
\-\ presenting\\:\\ 0\\.014511665127921371\ \(0\)\
\-\ slightly\\:\\ 0\\.01439260940940447\ \(0\)\
\-\ in\\:\\ 0\\.014046574338008497\ \(0\)\
\-\ worsening\\:\\ 0\\.014018666543336658\ \(0\)\
\-\ extremities\\:\\ 0\\.013965360912253701\ \(0\)\
\-\ headaches\\:\\ 0\\.013610176412796993\ \(0\)\
\-\ course\\:\\ 0\\.013435547681065172\ \(0\)\
\-\ which\\:\\ 0\\.013292871560354573\ \(0\)\
\-\ weakness\\:\\ 0\\.013223380637618269\ \(0\)\
\-\ diagnosed\\:\\ 0\\.01309247981997919\ \(0\)\
\-\ extremity\\:\\ 0\\.013021495706843491\ \(0\)\
\-\ intensity\\:\\ 0\\.01286946115158042\ \(0\)\
\-\ new\\:\\ 0\\.01240744990333566\ \(0\)\
\-\ was\\:\\ 0\\.012353469027671087\ \(0\)\
\-\ first\\:\\ 0\\.011947847644941051\ \(0\)\
\-\ \\,\\:\\ 0\\.011279586063220307\ \(0\)\
\-\ examination\\:\\ 0\\.011068429314477355\ \(0\)\
\-\ no\\:\\ 0\\.010755551883797525\ \(0\)\
\-\ decreased\\:\\ 0\\.010586485011352332\ \(0\)\
\-\ years\\:\\ 0\\.01045517973757701\ \(0\)\
\-\ abnormal\\:\\ 0\\.01015455100131213\ \(0\)\
\-\ time\\:\\ 0\\.010056671780163803\ \(0\)\
\-\ chronic\\:\\ 0\\.010029123470445832\ \(0\)\
\-\ he\\:\\ 0\\.00993411392513758\ \(0\)\
\-\ shows\\:\\ 0\\.00978905708220366\ \(0\)\
\-\ therapy\\:\\ 0\\.009519336651002554\ \(0\)\
\-\ signal\\:\\ 0\\.00938780970946991\ \(0\)\
\-\ patients\\:\\ 0\\.009214894164025107\ \(0\)\
\-\ on\\:\\ 0\\.009048637654567851\ \(0\)\
\-\ consistent\\:\\ 0\\.008730409453463346\ \(0\)\
\-\ bilateral\\:\\ 0\\.00864090720547685\ \(0\)\
\-\ small\\:\\ 0\\.00820239701825466\ \(0\)\
\-\ demonstrate\\:\\ 0\\.008193550588887669\ \(0\)\
\-\ case\\:\\ 0\\.007789601803613628\ \(0\)\
\-\ have\\:\\ 0\\.0077101586598545485\ \(0\)\
\-\ but\\:\\ 0\\.007593763754306406\ \(0\)\
\-\ female\\:\\ 0\\.0073198344643659735\ \(0\)\
\-\ treatment\\:\\ 0\\.007206737331670363\ \(0\)\
\-\ to\\:\\ 0\\.007117801807383104\ \(0\)\
\-\ the\\:\\ 0\\.006336425548916182\ \(0\)\
\-\ disease\\:\\ 0\\.005819739755065434\ \(0\)\
\-\ normal\\:\\ 0\\.005581718560829588\ \(0\)\
\-\ be\\:\\ 0\\.005490653013933038\ \(0\)\
\-\ from\\:\\ 0\\.005276815471475885\ \(0\)\
\-\ an\\:\\ 0\\.0049236036011863745\ \(0\)\
\-\ at\\:\\ 0\\.00482401313679847\ \(0\)\
\-\ is\\:\\ 0\\.00468575648653938\ \(0\)\
\-\ this\\:\\ 0\\.004004738388808888\ \(0\)\
\-\ year\\:\\ 0\\.003983771955303811\ \(0\)\
\-\ with\\:\\ 0\\.0039001392029963246\ \(0\)\
\-\ old\\:\\ 0\\.003645560820259394\ \(0\)\
\-\ patient\\:\\ 0\\.00356913304548495\ \(0\)\
\-\ for\\:\\ 0\\.003037950619344646\ \(0\)\
\-\ and\\:\\ 0\\.003000150095536974\ \(0\)\
\-\ of\\:\\ 0\\.0024271625166247587\ \(0\)\
\-\ \\.\\:\\ 0\\.0019228915386062567\ \(0\)\
\-\ a\\:\\ 0\\.001652499174244172\ \(0\)\
